Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0WGCDI)
| ADC Name |
Oberotatug ravtansine
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
oberotatug ravtansine; MEN1309; OBT076
Click to Show/Hide
|
|||||
| Organization |
Oxford BioTherapeutics (Originator);Menarini
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
Oberotatug
|
Antibody Info | ||||
| Antigen Name |
Lymphocyte antigen 75 (LY75)
|
Antigen Info | ||||
| Payload Name |
DM4
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
ravtansine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Unspecific non-hodgkin lymphoma | ||||
| Lung cancer | ||||
| Breast cancer | ||||
| Urothelial cancer | ||||
| Head and neck cancer | ||||
| Unspecific solid tumor |